Navigation Links
Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Date:10/1/2013

CORK, Ireland, Oct. 1, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will take place November 1 to 5 in Washington, D.C.

"Simeprevir's clinical profile has been characterized through a robust clinical development program including more than 3,700 patients," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen. "The study results that will be presented at the AASLD Annual Meeting support the potential utility of simeprevir in a number of different hepatitis C patient populations."

Simeprevir was approved in Japan in September 2013 for the treatment of genotype 1 hepatitis C. In the U.S., the New Drug Application (NDA) filed by Janssen for simeprevir administered once daily in combination with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients was granted Priority Review designation by the Food and Drug Administration (FDA) in May. Simeprevir is also being studied in several interferon-free regimens using selected combinations of direct-acting antiviral agents with different mechanisms of action.

The data to be presented at the 2013 AASLD Annual Meeting include:

Poster Presentations: HCV Therapeutics: New Agents, Poster Hall, November 3, 8:00 a.m. - 5:30 p.m. (EST)

  • Simeprevir (TMC435) with peg-interferon alpha-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Efficacy and safety in patient sub-populations in the PROMIS
    '/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
2. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
3. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
4. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
5. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
9. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
10. Bulgaria Launches Development of National Hepatitis Plan
11. Major Breakthrough in Hepatitis C Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , August 29, 2014 ... participate in the inaugural Tweetchat taking place in ... Worldwide , organised by UBM Live , ... #CPhIChat is a first of its kind global ... across the supply chain, aimed to stimulate conversations ...
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces that ... in its catalogue: Needle-Free Delivery: ... http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html Report ... and commercial prospects What does the future ... brand new report shows you the potential ...
(Date:8/28/2014)... DALLAS , Aug. 28, 2014 /PRNewswire-iReach/ -- ... Poland (Photo - ... " CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland ... identifies key trends in the healthcare market and ... and healthcare infrastructure. Most importantly, the report provides ...
Breaking Medicine Technology:CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 2Needle-Free Delivery: Technology and Market Forecast 2014-2024 3Needle-Free Delivery: Technology and Market Forecast 2014-2024 4Needle-Free Delivery: Technology and Market Forecast 2014-2024 5Needle-Free Delivery: Technology and Market Forecast 2014-2024 6Needle-Free Delivery: Technology and Market Forecast 2014-2024 7Needle-Free Delivery: Technology and Market Forecast 2014-2024 8Needle-Free Delivery: Technology and Market Forecast 2014-2024 9Needle-Free Delivery: Technology and Market Forecast 2014-2024 10Needle-Free Delivery: Technology and Market Forecast 2014-2024 11Needle-Free Delivery: Technology and Market Forecast 2014-2024 12Needle-Free Delivery: Technology and Market Forecast 2014-2024 13Needle-Free Delivery: Technology and Market Forecast 2014-2024 14Needle-Free Delivery: Technology and Market Forecast 2014-2024 15Needle-Free Delivery: Technology and Market Forecast 2014-2024 16Needle-Free Delivery: Technology and Market Forecast 2014-2024 17Needle-Free Delivery: Technology and Market Forecast 2014-2024 18Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... AMSTERDAM, May 30 Amsterdam Molecular,Therapeutics (Euronext: AMT), ... therapy,today announced that positive interim data from its ... were presented by the,Principal Investigator, professor Daniel Gaudet, ... in Boston on May 29th. These data confirm ...
... CHELMSFORD, Mass., May 29 Magellan Biosciences, ... feature,automated systems and assays designed to streamline ... at the 108th meeting of the,American Society ... and Dynex Technologies, will share booth 743 ...
Cached Medicine Technology:AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 2AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011 3Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 2Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 3
(Date:8/29/2014)... HealthDay Reporter THURSDAY, Aug. ... American babies are getting the vaccines they need to ... Thursday. More than 90 percent of children are ... (MMR); polio; hepatitis B and chickenpox (varicella), according to ... "Nationally, vaccination among children 19 to 35 months of ...
(Date:8/29/2014)... Floors of hospitals and other medical facilities tend ... patients are relegated to lying down or sitting due ... Two inventors from Perrysburg, Ohio, have designed the patent-pending ... special pair of socks helps prevent slips and falls ... relegated to beds or chairs from standing and walking ...
(Date:8/29/2014)... -- Selling cigarettes in plain packages doesn,t increase the ... sales in small stores, according to new research from ... industry when it tried to prevent Australia from becoming ... packaging for tobacco products in 2012. Similar legislation is ... Researchers surveyed nearly 2,000 adult smokers in Australia ...
(Date:8/29/2014)... Vancouver, BC (PRWEB) August 29, 2014 ... announced that the company will now be selling purse-sized ... in such a way that they can be carried ... are they portable, the purse-sized range at Honey Gifts ... A long battery life and rechargeable batteries are common ...
(Date:8/29/2014)... CA (PRWEB) August 29, 2014 Evolutions ... Santa Barbara in the Santa Barbara News-Press Readers’ Choice ... won the Readers’ Choice poll as Best Medical Spa. ... 2014 reads the following about Evolutions Medical Spa recognition: ... but it is recognized as a top-notch, cutting-edge medical ...
Breaking Medicine News(10 mins):Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Study Counters Critics of Plainer Cigarette Packaging 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3
... A team of international health experts issues a bold call ... They appeal to fund the salaries of health workers or ... diseases are made available in poor countries but there are ... from the inside of the Global Fund," say Gorik Ooms ...
... scarcity has become a universal problem. With a view ... taken up in the country.// ,In a press ... annual rainfall in India is about 1170 mm. However, ... ,The release further said that there had been ...
... of the central nervous system [CNS] in animal evolution ... evolved// from the same ancestor, but their CNSs are ... their lineages had split during evolution. Researchers from the ... that the vertebrate nervous system is probably much older ...
... violence, noise, poor housing or other chronic risk factors ... tissues than other young people. ,However, when ... these negative physiological changes, reports a new study from ... that the cardiovascular systems of youths who are exposed ...
... no monthly bleeding in women or menstruation may come as welcome ... believe it to be the symbol of fertility and would not ... ,This has created a major uproar in the health world ... new pill called Lybrel. This pill is designed to eliminate periods ...
... effective way to fight leukemia might be to knock out ... new study// shows. ,The findings suggest that a ... own be an effective therapy. ,But such a ... offer an effective one-two punch against drug-resistant forms of chronic ...
Cached Medicine News:Health News:Health Expert’s Appeal to Global Fund to Fight HIV, TB and Malari 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:The Origin of the Brain Lies in a Worm 2Health News:Family Turmoil and Violence Results in Stress-induced Physical Problems in Young, Cornell Psychologist Finds 2Health News:Period Eliminating Pills 2Health News:Knocking Out Survival Protein Could Aid Leukemia Treatment 2
... Physician-office® is an internet ... (Solo practice, group practice ... complete their normal duties ... is a front office ...
... is a modular, Electronic Medical Record (EMR) system ... create a patient chart. ChartMaker is an ... M compliant patient notes, medical reports, letters, and ... ChartMaker is designed to be installed in a ...
... original EMR companies, with a wealth and ... With over a decade of clinical and ... design, corporate level training and support, enables ... medical practice to EMR. The unparalleled HL7 ...
... is dedicated to serving the needs ... ultimate tool to,run a better orthopaedic ... records software.,AcerMed's Orthopaedic-Edition EMR software has ... surgeons across the country resulting in ...
Medicine Products: